Novo Nordisk (NVO) Gets a Buy Rating from Deutsche Bank


According to The Fly, deutsche Bank analyst Tim Race maintained a Buy rating on Novo Nordisk (NVO) yesterday. The company’s shares closed yesterday at $45.95.

Race has an average return of 0.6% when recommending Novo Nordisk.

According to TipRanks.com, Race is ranked #2316 out of 5108 analysts.

The the analyst consensus on Novo Nordisk is currently a Moderate Buy rating.

See today’s analyst top recommended stocks >>

Novo Nordisk’s market cap is currently $84.25B and has a P/E ratio of 17.90. The company has a Price to Book ratio of 14.30.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts